Compare SLVM & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLVM | IOVA |
|---|---|---|
| Founded | 1898 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2021 | 2008 |
| Metric | SLVM | IOVA |
|---|---|---|
| Price | $38.58 | $4.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $54.00 | $9.00 |
| AVG Volume (30 Days) | 312.4K | ★ 13.6M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,351,000,000.00 | N/A |
| Revenue This Year | $0.93 | $47.74 |
| Revenue Next Year | $1.54 | $40.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.53 | $1.76 |
| 52 Week High | $56.80 | $5.63 |
| Indicator | SLVM | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 62.80 |
| Support Level | $36.87 | $2.08 |
| Resistance Level | $43.60 | $5.63 |
| Average True Range (ATR) | 1.48 | 0.39 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 43.81 | 80.29 |
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.